Keywords
Human Immunodeficiency Virus
implementation
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the implementation of the Pharmaceutical Service for Post-Exposure Prophylaxis (PEP) in an Emergency Care Unit in a city in the state of Pará, considering the organization of care, adherence to therapy, and the incorporation of technologies. Methods: A qualitative-quantitative, action-research study was conducted in an Emergency Care Unit. Participants were HIV-positive individuals indicated for PEP use. The intervention included the implementation of the Pharmaceutical Service for PEP, with health education actions, pharmacotherapeutic follow-up, adherence assessment using the Morisky-Green test, and analysis of seroconversion occurrence. Results: A predominance of heterosexual women, of mixed race, and with secondary/technical education was observed. In-person and telehealth pharmacotherapeutic follow-up resulted in 70.6% adherence and no seroconversion. Conclusion: The implementation of the pharmaceutical consultation room, the Standard Operating Procedure, and care technologies improved workflows and standardized procedures. Health education broadened the community's knowledge and strengthened multiprofessional integration. The findings highlighted the relevance of pharmaceutical services in combined prevention, adherence, and the absence of seroconversion in strengthening the PEP care pathway within the Brazilian Unified Health System (SUS).
References
BRASIL. Ministério da Saúde. Secretaria de Atenção à Saúde. Política Nacional de Humanização: Atenção Básica. Brasília: Ministério da Saúde; 2010.
BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Boletim Epidemiológico HIV/Aids 2023. Brasília: Ministério da Saúde; 2023.
BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância, Prevenção e Controle das IST, do HIV/Aids e das Hepatites Virais. Protocolo Clínico e Diretrizes Terapêuticas para Profilaxia Pós-Exposição (PEP) de Risco à Infecção pelo HIV, IST e Hepatites Virais. Brasília: Ministério da Saúde; 2021.
CONSELHO FEDERAL DE FARMÁCIA (CFF). Guia de Atuação do Farmacêutico na Profilaxia Pós-Exposição ao Risco de Infecção pelo HIV (PEP). Brasília: Conselho Federal de Farmácia; 2023.
CONSELHO FEDERAL DE FARMÁCIA (CFF). Resolução nº 727/2022. Regulamenta a Telefarmácia no Brasil. Brasília: CFF; 2022.
CORRÊA ACP, BRITO AG, SOLER O, et al. Serviços Farmacêuticos e Profilaxia Pós-Exposição ao HIV: Revisão de Escopo. Revista Contemporânea, 2024; 4(12): e7144.
HORBERG MA, et al. Assessing the effectiveness of pharmacy-based adherence interventions on antiretroviral adherence in persons with HIV. Journal of Acquired Immune Deficiency Syndromes, 2006.
IBGE. Censo Demográfico 2022: resultados gerais. Rio de Janeiro: IBGE; 2023.
MINAYO MCS, COSTA AP. Fundamentos teóricos das técnicas de investigação qualitativa. Revista Lusófona de Educação, 2018; 40: 11-25.
OLAYEMI SO, et al. Improving pharmacy practice through public health programs: experience from Global HIV/AIDS Initiative Nigeria project. SpringerPlus, 2013; 2: 525.
OLIVEIRA Í, et al. A implementação da Profilaxia Pré-Exposição (PrEP) e Pós-Exposição (PEP) no SUS: desafios, impactos e perspectivas na prevenção ao HIV. Revista Tópicos, 2024; 2(16).
PINTO L, et al. Cuidado farmacêutico na profilaxia pré e pós-exposição ao HIV: perspectivas para a humanização e ampliação do acesso no SUS. REASE, 2025.
PROTOCOLO CLÍNICO E DIRETRIZES TERAPÊUTICAS (PCDT) para Profilaxia Pós-Exposição (PEP) de Risco à Infecção pelo HIV, IST e Hepatites Virais. Brasília: Ministério da Saúde; 2024.
SMITH A, et al. Pharmacy-based interventions to increase use of HIV PrEP. AIDS and Behavior, 2021.
SOUSA A, ANDRADE F. Atenção farmacêutica na adesão à terapia antirretroviral do HIV/AIDS. Revista REMS, 2022.
SPRINZ E, et al. Rotinas em HIV e Aids. Porto Alegre: Artes Médicas Sul; 1999.
THIOLLENT M. Metodologia da pesquisa-ação. São Paulo: Cortez; 2022.
TRICCO AC, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med, 2018; 169(7): 467-473.
UNAIDS. Global AIDS Update 2023: The Path That Ends AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2023.
VELLA S, SCHWARTLÄNDER B, SOW SP, et al. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS, 2012; 26(10): 1231-1241.
WORLD HEALTH ORGANIZATION. New WHO recommendations to accelerate progress on TB. Geneva: World Health Organization; 2019.